Form 4: Vertex Legal Officer Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Vertex Pharmaceuticals' EVP and Chief Legal Officer, Jonathan Biller, reported the sale of company common stock, including shares withheld for tax purposes, under a pre-arranged trading plan.
Summary
- Jonathan Biller, Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals Inc. (VRTX), reported transactions involving the company's common stock.
- On October 1, 2025, 1,259 shares of common stock were disposed of at a price of $400.00 per share, identified as a disposition for tax withholding purposes.
- On October 2, 2025, an additional 694 shares of common stock were sold at a price of $404.21 per share.
- The sale on October 2, 2025, was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Biller established on February 24, 2025.
- Following these reported transactions, Mr. Biller directly holds 15,653 shares of Vertex Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The filing reports a routine insider stock sale, including shares withheld for tax purposes, executed under a pre-arranged 10b5-1 trading plan. This type of transaction is common and generally does not convey a strong positive or negative sentiment regarding the company's operational performance or future prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This routine insider transaction, executed under a Rule 10b5-1 plan, is a common occurrence in the pharmaceutical industry and does not inherently reflect broader industry trends or competitive positioning. Such plans are often used by executives for personal financial planning while adhering to insider trading regulations.
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in insider ownership, which is a routine event, especially when conducted under a 10b5-1 plan, and is unlikely to have a significant impact on shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 02/24/2025 | Date Mr. Biller's company-approved Rule 10b5-1 trading plan was entered into. |
| 10/01/2025 | Date of disposition of 1,259 shares of common stock for tax withholding. |
| 10/02/2025 | Date of sale of 694 shares of common stock. |
| 10/03/2025 | Date the Form 4 was signed and filed. |
Keywords
VRTX, Vertex Pharmaceuticals, Jonathan Biller, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.